Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02146352 · ClinicalTrials.gov registry record · NA
AXIOS Stent With Electrocautery Enhanced Delivery System
A NA study of Pancreatic Pseudocyst(s), sponsored by Xlumena.
- Completed
- Registry status
- NA
- Development phase
- 30
- Enrollment target
- 8
- Study locations
NCT02146352 is a NA study of Pancreatic Pseudocyst(s) that has completed, run by Xlumena. The registered enrollment target is 30 participants. The trial reports 8 study locations across 7 states.
The verdict
NCT02146352, a NA study of Pancreatic Pseudocyst(s), has completed, sponsored by Xlumena.
- COMPLETED
- Registry status
- NA
- Development phase
- 30 participants
- Enrollment target
- 8
- Study locations
Study Summary
The purpose of this study is to demonstrate the safety and effectiveness of the AXIOS Stent with Electrocautery Enhanced Delivery System for endoscopic transenteric drainage of pancreatic pseudocysts.
Conditions Studied
Interventions
- DEVICE AXIOS Stent with Electrocautery Enhanced Delivery System
Study Locations (8)
Florida
- Baptist Medical Center - Jacksonville
- Florida Hospital - Orlando
Colorado
- University of Colorado Denver - Aurora
Georgia
- Emory University - Atlanta
Illinois
- University of Chicago Medical Center - Chicago
Maryland
- Johns Hopkins University - Baltimore
Missouri
- Washington University in St. Louis - St Louis
Pennsylvania
- Thomas Jefferson University - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2014-06 |
| Est. Completion | 2015-03 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02146352
The ClinicalTrials.gov registry entry for NCT02146352 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Xlumena, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Pancreatic Pseudocyst(s) appearing as the primary indexed condition, and to 1 intervention - of which AXIOS Stent with Electrocautery Enhanced Delivery System is the first listed.
NCT02146352 reports 8 study locations spanning 7 distinct geographic areas - top geographies include Florida, Colorado, Georgia.
Frequently Asked Questions
What is clinical trial NCT02146352 about?
NCT02146352 is a clinical study titled "AXIOS Stent With Electrocautery Enhanced Delivery System". The purpose of this study is to demonstrate the safety and effectiveness of the AXIOS Stent with Electrocautery Enhanced Delivery System for endoscopic transenteric drainage of pancreatic pseudocysts.
What is the current status of trial NCT02146352?
This trial is currently completed. It is a NA study. The enrollment target is 30 participants. The study started on 2014-06. Estimated completion is 2015-03.
What conditions does trial NCT02146352 study?
This clinical trial studies the following conditions: Pancreatic Pseudocyst(s).
What interventions are being tested in trial NCT02146352?
The interventions under investigation include: AXIOS Stent with Electrocautery Enhanced Delivery System (DEVICE).
Who is sponsoring clinical trial NCT02146352?
This trial is sponsored by Xlumena, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02146352 being conducted?
This trial has 8 study locations across Colorado, Florida, Georgia, Illinois, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.